New hope for HS sufferers: Long-Term drug trial shows promise
NCT ID NCT06241573
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at the long-term safety and effectiveness of spesolimab for people with hidradenitis suppurativa (HS), a painful skin condition. Participants who completed a prior spesolimab study receive injections under the skin every 2 weeks for about 1.5 years. The goal is to see how well the drug is tolerated and if it helps control HS over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA (HS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ASMC-IPSMC-skin and Veneral Diseases
Sofia, 1407, Bulgaria
-
Alfred Hospital
Melbourne, Victoria, 3004, Australia
-
Clinical Trials Research Institute
Thousand Oaks, California, 91320, United States
-
Dermatology Research Associates
Los Angeles, California, 90045, United States
-
Dr. S. K. Siddha Medicine Professional Corporation
Newmarket, Ontario, L3Y 5G8, Canada
-
Fachklinik Bad Bentheim
Bad Bentheim, 48455, Germany
-
First OC Dermatology
Fountain Valley, California, 92708, United States
-
Guelph Dermatology Research
Guelph, Ontario, N1L 0B7, Canada
-
HOP Privé Antony
Antony, 92160, France
-
Hautmedizin Saar
Merzig, 66663, Germany
-
Holdsworth House Medical Practice
Sydney, New South Wales, 2010, Australia
-
Hospital Alemán
Capital Federal, C1118AAT, Argentina
-
Hospital Italiano de Buenos Aires
CABA, C1199ABB, Argentina
-
Hospital Kuala Lumpur
Kuala Lumpur, 50586, Malaysia
-
Hospital Pulau Pinang-Pulau Pinang-21953
Georgetown Pulau Pinang, 10990, Malaysia
-
Hospital Sultan Ismail
Johor Bahru, 81100, Malaysia
-
Hospital Universitario Miguel Servet
Zaragoza, 50009, Spain
-
Hospital of Lithuanian University of Health Sciences Kauno Klinikos
Kaunas, 50161, Lithuania
-
Hôpital Edouard Herriot
Lyon, 69437, France
-
Integrative Skin Science and Research-Sacramento-69402
Sacramento, California, 95815, United States
-
Kurume University Hospital
Fukuoka, Kurume, 830-0011, Japan
-
Medical Center "Kordis"
Pleven, 5800, Bulgaria
-
National University Hospital-Singapore-42005
Singapore, 119074, Singapore
-
Nihon University Itabashi Hospital
Tokyo, Itabashi-ku, 173-8610, Japan
-
Non-Public Health Care Facility LABDERM
Ossy, 42624, Poland
-
Ogaki Municipal Hospital
Gifu, Ogaki, 503-8502, Japan
-
Provita Clinic
Warsaw, 02-647, Poland
-
Royalderm
Warsaw, 02-962, Poland
-
STAT Research
CABA, C1023AAB, Argentina
-
Sarawak General Hospital
Kuching, 93586, Malaysia
-
Seoul National University Hospital
Seoul, 03080, South Korea
-
SimcoDerm Medical and Surgical Dermatology Centre
Barrie, Ontario, L4M 7G1, Canada
-
Sunway Medical Centre
Selangor Darul Ehsan, 47500, Malaysia
-
The University of Tokyo Hospital
Tokyo, Bunkyo-ku, 113-8655, Japan
-
Tokyo Medical University Hospital
Tokyo, Shinjuku-ku, 160-0023, Japan
-
Vilnius University Hospital, Santariskiu
Vilnius, 08411, Lithuania